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Abstract
Background: It is increasingly clear that some heat shock proteins (Hsps) play a role in inflammation. Here, we report results
showing participation of Hsp60 in the pathogenesis of chronic obstructive pulmonary diseases (COPD), as indicated by data
from both in vivo and in vitro analyses.
Methods and Results: Bronchial biopsies from patients with stable COPD, smoker controls with normal lung function, and
non-smoker controls were studied. We quantified by immunohistochemistry levels of Hsp10, Hsp27, Hsp40, Hsp60, Hsp70,
Hsp90, and HSF-1, along with levels of inflammatory markers. Hsp10, Hsp40, and Hsp60 were increased during progression
of disease. We found also a positive correlation between the number of neutrophils and Hsp60 levels. Double-
immunostaining showed that Hsp60-positive neutrophils were significantly increased in COPD patients. We then
investigated in vitro the effect on Hsp60 expression in bronchial epithelial cells (16HBE) caused by oxidative stress, a
hallmark of COPD mucosa, which we induced with H2O2. This stressor determined increased levels of Hsp60 through a gene
up-regulation mechanism involving NFkB-p65. Release of Hsp60 in the extracellular medium by the bronchial epithelial cells
was also increased after H2O2 treatment in the absence of cell death.
Conclusions: This is the first report clearly pointing to participation of Hsps, particularly Hsp60, in COPD pathogenesis.
Hsp60 induction by NFkB-p65 and its release by epithelial cells after oxidative stress can have a role in maintaining
inflammation, e.g., by stimulating neutrophils activity. The data open new scenarios that might help in designing efficacious
anti-inflammatory therapies centered on Hsp60 and applicable to COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality worldwide [1]. It is character-
ized by airflow limitation that is not fully reversible, usually
progressive and associated with an abnormal inflammatory
response of the lung to noxious particles or gases [1]. Inflam-
mation in COPD occurs in the central and peripheral airways as
well as in lung parenchyma [2]. Management of patients with
COPD is directed to maintain a stable condition, avoiding
exacerbation episodes. However, a chronic inflammatory status
in airways of stable COPD patients is present and is characterised
by an increased number of CD8 lymphocytes, macrophages, and
neutrophils [2].
Heat shock proteins (Hsps)-chaperones (hereinafter Hsps) are
paradoxical molecules with beneficial, protective roles intracellu-
larly but with potentially pathogenetic effects as they can initiate/
perpetuate inflammation when secreted outside cells [3]. Intra-
cellular Hsps have predominantly a cytoprotective effect in the
lung [4–6]. By contrast, extracellular Hsps are signal molecules
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for the immune system, modulating the secretion of pro-
inflammatory cytokines [7–11]. Although changes in the levels
of Hsp60 and Hsp10 have been reported during bronchial
carcinogenesis [12,13], one of the most severe complications for
COPD patients, participation of Hsps in COPD pathogenesis and
progression has not, to our knowledge, been examined in any
detail. For these reasons, we investigated in the bronchial mucosa
the presence and levels of various Hsps and a pertinent
transcription factor (i.e., heat shock factor-1, HSF-1), in relation
to the COPD status.
Bronchial biopsies obtained from patients with mild/moderate
and severe/very severe stable COPD, and control groups of either
healthy smokers with normal lung function or non-smoking
subjects, were studied applying a battery of complementary
methods and experimental approaches. The in vivo results led us
to focus on the mechanism of Hsp60 induction by oxidative stress,
a hallmark of COPD mucosa, using in vitro experiments. All
together, our results suggest a direct involvement of Hsp60 in
COPD pathogenesis.
Results
Clinical characteristics of subjects studied
We obtained and studied bronchial biopsies from 55 Caucasian
subjects: 32 had a diagnosis of COPD in a stable clinical state
[1,14], 12 were current or ex smokers with normal lung function,
and 11 were non-smokers with normal lung function (Table 1).
COPD patients were divided in two groups, according to their
clinical stage (stage I–II: mild/moderate; or stage III–IV: severe/
very severe; n= 14 and n= 18, respectively) [1]. Subjects in all
groups were age-matched. The smoking history was similar in the
three smoker groups: mild/moderate and severe/very severe
COPD, and healthy smokers with normal lung function. Values of
FEV1 (% predicted) and FEV1/FVC (%) were significantly
different in the groups with mild/moderate and severe/very
severe COPD compared to both control groups (healthy smokers
and healthy non-smokers). Severe/very severe COPD patients also
differed significantly from mild/moderate COPD patients (for
overall groups, ANOVA test: p,0.0001 for FEV1% predicted and
FEV1/FVC% values). Forty-one percent (n = 13) of the total
COPD patients and 33% (n= 4) of healthy smokers with normal
lung function also had symptoms of chronic bronchitis. There was
no significant difference when COPD patients and healthy
smokers were compared for the presence of chronic bronchitis
(x2, p = 0.658).
Measurement of inflammatory markers in the bronchial
lamina propria showed increased levels of neutrophils,
macrophages, and CD8 lymphocytes in COPD
We characterized and quantified several inflammatory markers in
all specimens of airways mucosa obtained from stable COPD patients
by immunohistochemistry. Measurements were made in the lamina
propria of the mucosa. The results are summarized in Table 2. The
number of neutrophils was significantly higher in the bronchial lamina
propria of severe/very severe (median 173, range [47–500]) COPD
patients compared with control smokers (101 [17–308], p=0.011) and
non-smokers (89 [59–179], p=0.010). The number of myeloperox-
idase (MPO) positive neutrophils was significantly higher in the lamina
propria of severe/very severe (242 [129–387]) COPD patients than in
the other three groups (p=0.0009, p=0.0016 and p=0.047, in
comparison with control non smokers, control healthy smokers and
mild/moderate COPD, respectively). Compared with control non-
smokers (284 [110–516]), the number of CD68 positive macrophages
was significantly higher in severe/very severe (428 [204–1054],
p=0.033) and mild/moderate (566 [158–833], p=0.036) COPD.
Also the number of CD8 positive lymphocytes was significantly
increased in severe/very severe (215 [59–355], p=0.021) and mild/
moderate (208 [86–523], p=0.027) COPD compared to control non-
smokers (120 [15–301]). The numbers of CD4- and FoxP3-positive
cells did not differ significantly in the four groups of subjects. COPD
patients with chronic bronchitis had a similar number of neutrophils
and MPO-positive cells when compared with COPD patients without
chronic bronchitis (not shown).
Hsp10, Hsp40 and Hsp60 levels were increased in COPD
We quantified the levels of six Hsps and of HSF1 in bronchial
mucosa of all subjects by immunohistochemistry. We quantified cell
positivity separately in epithelium and in lamina propria (Table 3).
All molecules were present in various percentages in epithelium
and lamina propria of all groups. However, only Hsp10, Hsp40,
and Hsp60 levels were increased in the bronchial epithelium of
severe/very severe COPD compared to control non-smokers
(Mann Whitney: p= 0.007, 0.020, and 0.006, respectively)
(Figures 1 and 2). No significant differences were observed in the
bronchial epithelium among the four groups of subjects for all
other proteins investigated (not shown).
In lamina propria, a number of inflammatory cells, fibroblasts
and smooth muscle cells were also positive for Hsps. Hsp27 was
the most abundant Hsp observed in the bronchial lamina propria
but without significant differences between the four groups of
subjects. The number of Hsp60-positive cells was significantly
Table 1. Clinical characteristics of subjects studied.
Group n
Age
(years) M/F
Smoking
history (p-y)
Ex/current
smokers
FEV1 preb2
(% predicted)
FEV1 postb2
(% predicted)
FEV1/FVC
(%)
Control non-smokers 11 676 10 10/1 0 0 116614 ND 85610
Control smokers with
normal lung function
12 6167 9/3 43626 2/10 104613 ND 8166
Mild/moderate COPD 14 6768 12/2 40619 5/9 66614# 72612 6068#
Severe/very severe COPD 18 6669 11/7 54636 13/5 3568#& 3869 44610#&
Patients were classified according to GOLD (http://www-goldcopd.com) levels of severity for COPD into: mild/moderate (stages I–II) and severe/ very severe (stages III–
IV).
Data are mean6SD. For COPD patients FEV1/FVC (%) are post-bronchodilator values.
Abbreviations: n, number of subjects; M, male; F, female, FEV1: forced expiratory volume in one second; FVC, forced vital capacity; ND, not determined; COPD, chronic
obstructive pulmonary disease. Statistics. (ANOVA) #, p,0.0001, significantly different from control smokers with normal lung function and control never-smokers; &,
p,0.0001, significantly different from mild/moderate COPD.
doi:10.1371/journal.pone.0028200.t001
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higher in severe/very severe COPD compared to control smokers
with normal lung function (Figure 1 and 2). The number of Hsp10
and Hsp40 positive cells was significantly increased in all stages of
stable COPD compared to control smokers with normal lung
function and non smoking subjects (Figure 1 and 2). No significant
differences were observed in the bronchial lamina propria among
the four groups of subjects for all other proteins investigated.
COPD patients with chronic bronchitis had a similar number of
Hsp10, Hsp40, and Hsp60 positive cells when compared with
COPD patients without chronic bronchitis (not shown).
RT-PCR in bronchial biopsies did not show differences in
Hsp mRNA levels between the groups of patients
We performed a set of RT-PCR experiments to obtain clues
about the mechanism, transcriptional or post-transcriptional gene
regulation, responsible for Hsps increase in bronchial mucosa of
COPD patients. Hsp10, Hsp40, and Hsp60 mRNAs levels did
not differ significantly in the four groups of patients studied
(Table 4).These results point to the occurrence of post-
transcriptional events and/or the invasion of the mucosa by
Hsps from other sources, as the cause of increased Hsp levels,
in vivo.
Correlation analysis between Hsps protein levels, clinical
characteristics, and inflammatory markers showed a
correlation only between neutrophils and Hsp60
We determined the correlation between Hsps and HSF-1
levels and either clinical characteristics or inflammatory markers.
In all smokers, the number of Hsp60 positive cells in the lamina
propria correlated positively and significantly with the number
Table 2. Inflammatory markers in bronchial mucosa.
Target Lamina propria (cells/mm
2)
Control
non-smokers
Control smokers with
normal lung function
Mild/moderate
COPD
Severe/very
severe COPD p value
CD4 168 (88–378) 218 (37–500) 245 (86–731) 252 (42–671) 0.360
CD8 120 (15–301) 187 (78–657) 208 (86–523) # 215 (59–355) # 0.125
CD68 284 (110–516) 369 (97–945) 566 (158–833) # 428 (204–1054) # 0.130
Neutrophil Elastase 89 (58–179) 101 (17–308) 125 (28–512) 173 (47–500) #e 0.030
MPO 120 (54–250) 105 (43–258) 158 (64–306) 242 (129–387) #e^ 0.003
FoxP3 86 (32–177) 105 (23–155) 92 (12–187) 86 (19–306) 0.990
Abbreviations: COPD, chronic obstructive pulmonary disease; MPO, myeloperoxidase; FoxP3: forkhead box P3. Data expressed as median (range). Statistics: Kruskal-
Wallis test for multiple comparisons. For comparison between groups the Mann-Whitney U test was applied: #, p,0.05, significantly different from control non
smokers; e, p,0.05, significantly different from control smokers with normal lung function; ^, p,0.05, significantly different from mild/moderate COPD. The exact ‘‘p’’
values for comparison between groups are given in the Results section.
doi:10.1371/journal.pone.0028200.t002
Table 3. Immunohistochemical quantification of Hsp and HSF-1 proteins in bronchial mucosa.
Protein in:
Control
non-smokers
Control smokers with
normal lung function
Mild/moderate
COPD
Severe/very
severe COPD p value
Bronchial epithelium (score 0-3)
Hsp10 1.0 (0.2–1.7)c 0.5 (0.2–2.5) 1.5 (0.2–3.0) 2.0 (0.5–2.7) # 0.031
Hsp27 2.0 (0.5–3.0) 2.0 (1.5–3.0) 2.7 (1.7–3.0) 2.5 (1.2–3.0) 0.164
Hsp40 1.5 (0.5–2.5) 1.5 (0.5–3.0) 2.5 0.5–2.7) 2.5 (0.5–3.0) # 0.112
Hsp60 0.7 (0.5–1.5) 1.2 (0.5–2.5) 1.7 (0.5–3.0) 1.5 (0.5–2.5) # 0.053
Hsp70 1.7 (0.2–2.7) 1.0 (0.2–2.7) 1.0 (0.2–2.8) 2.1 (0.2–2.8) 0.353
Hsp90 2.1 (0.5–2.7) 2.2 (0.5–2.7) 2.5 (1.0–3.0) 2.5 (0.5–3.0) 0.588
pHSF1 1.0 (0.5–2.5) 0.5 (0.5–1.5) 0.7(0.5–2.5) 0.5 (0.5–2.5) 0.056
Lamina propria (cells/mm2)
Hsp10 97 (32–193) 126 (18–393) 233 (12–726) # 329 (68–639) #e 0.009
Hsp27 387 (161–581) 353 (214–597) 452 (341–914) 460 (183–897) 0.111
Hsp40 145 (40–376) 191 (32–536) 277 (129–440) #e 277 (54–753) # 0.032
Hsp60 113 (45–306) 115 (11–269) 161 (69–495) 193 (65–415) e 0.120
Hsp70 103 (11–339) 91 (32–258) 97 (8–510) 161 (16–581) 0.356
Hsp90 188 (45–446) 241 (81–581) 328 (97–702) 266 (142–779) 0.384
pHSF1 77 (64–226) 64 (32–183) 139 (16–235) 69 (32–363) 0.267
Abbreviations: COPD, chronic obstructive pulmonary disease; MPO, myeloperoxidase. Data expressed as median (range). Statistics: The Kruskal-Wallis test was used for
multiple comparisons followed by Mann-Whitney U test for comparison between groups: #, p,0.05, significantly different from control non smokers; e, p,0.05,
significantly different from control smokers with normal lung function; The exact ‘‘p’’ values for comparison between groups are given in the Results section.
doi:10.1371/journal.pone.0028200.t003
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of neutrophils (r = 0.512, p = 0.0058) and with activated
neutrophils expressing MPO (r = 0.513, p = 0.034) (Figure 3,
panels A and C). Significant correlations were also observed
when COPD patients were considered as a group (r = 0.488,
p = 0.0018 and r = 0.477, p = 0.019 for neutrophils and MPO
positive cells, respectively) (Figure 3, panels B and D). No other
significant correlations were found between the other stress
proteins investigated and any clinical parameter or inflammatory
marker.
Double immunohistochemical staining showed a
significantly higher number of neutrophils expressing
Hsp60 in COPD
The correlation between Hsp60 positive cells and neutrophils
reported above let us to perform double-immunostaining exper-
iments in four severe/very severe COPD patients and in four
control healthy smokers. A number of neutrophils showed
positivity for Hsp60 (Figure 2F, inset). In addition, the percentage
Figure 1. Measurement of Hsps in the bronchial epithelium and lamina propria: Comparison between groups of patients. Hsp10,
Hsp40, and Hsp60 immunopositive cells in the epithelium (top panels A, C, E) and in the lamina propria (bottom panels B, D, F) of the four groups
studied: Control non Smokers, Control Smokers, Mild/Moderate COPD, and Severe/Very Severe COPD. Results are expressed as the median and
interquartile range (IQR) of scored (0–3, vertical axis) immunopositivity in the epithelium, or as number of immunopositive cells per square millimeter
(vertical axis) in the lamina propria; ‘‘p’’ values are shown on top of the lines spanning the two groups being compared.
doi:10.1371/journal.pone.0028200.g001
Figure 2. Hsps in the bronchial epithelium and lamina propria: Representative images. Photomicrographs showing frozen sections of
bronchial mucosa from a control non smoker (A, C, E) and from a patient with severe stable COPD (B, D, F) immunostained to identify Hsp10 (A, B),
Hsp40 (C, D), and Hsp60 (E, F). Nuclei were counterstained with haematoxylin (blue). Cells positive for Hsps are in red. Inset in F shows a cell double
stained for neutrophil elastase (red) and Hsp60 (brown). Bar = 50 microns.
doi:10.1371/journal.pone.0028200.g002
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of neutrophils expressing Hsp60 was significantly higher in severe/
very severe stable COPD compared to control smokers with
normal lung function [mean 6 SD: 76 6 7% vs 25 6 14%,
respectively; p,0.050].
The in vitro Hsp60 expression and release in 16HBE
bronchial epithelial cells were induced by a typical
pulmonary stress pertinent to COPD
We found of considerable interest the increase of Hsp60 in
bronchial mucosa and the correlation of this increase with
neutrophils in COPD patients. It is known that neutrophils are
among the major players in inflammation in stable COPD patients
[14]. Accumulation of Hsp60 in neutrophils raises the question:
where does the Hsp60 come from? It is quite likely that neutrophils
produce their own Hsp60. However, one cannot ignore that
Hsp60 can reach neutrophils after release/secretion from other
cells, as suggested by published data (see Discussion). Thus, we
hypothesized that a proinflammatory stimulus, such as that due to
oxidative stress, determines Hsp60 increase in epithelial cells as
well as its release into the extracellular medium. To test this
hypothesis we performed experiments in vitro using a human
bronchial epithelial cell line (16HBE), which we had used before to
study the effects of oxidative stress on Hsp levels [15]. The cells
Table 4. Hsp mRNA levels, expressed as the ratio [mRNA of gene of interest] / [mRNA of housekeeping gene (GAPDH)], in the
bronchial mucosa.
Hsp
Control
non-smokers (n=7)
Control smokers with
normal lung function (n =8)
Mild/moderate
COPD (n=9)
Severe/very severe
COPD (n=9) p value
Hsp10 0.19 (0.09–0.27) 0.11 (0.05–0.52) 0.15 (0.11–0.80) 0.32 (0.14–0.93) 0.414
Hsp40 0.96 (0.03–2.15) 1.08 (0.41–5.65) 0.94 (0.67–2.21) 0.86 (0.13–4.11) 0.872
Hsp60 1.0 (0.68–1.49) 0.96 (0.21–1.87) 1.3 (0.35–2.17) 1.31 (0.92–4.97) 0.134
Abbreviations: COPD, chronic obstructive pulmonary disease, Hsp, heat shock protein. Data are median (range). Relative levels of mRNAs are expressed as the ratio
[mRNA gene of interest OD] / [mRNA housekeeping gene OD (GAPDH)]. Statistics: Kruskal-Wallis test was applied for multiple comparisons.
doi:10.1371/journal.pone.0028200.t004
Figure 3. Correlations between neutrophils and Hsp60. Regression analysis between number of Hsp60 positive cells (vertical axis) and number
of neutrophils (horizontal axis), panels A and B, and between number of Hsp60 positive cells (vertical axis) and number of MPO positive neutrophils
(horizontal axis), panels C and D, in the lamina propria of all smokers (panels A and C) and of patients with COPD alone, considered as a single group
(panels B and D).
doi:10.1371/journal.pone.0028200.g003
Active Role of Hsp60 in COPD Pathogenesis
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e28200
were treated with various concentrations of H2O2 and the effects
on viability/apoptosis of various doses and exposure times were
measured. The results indicated that treatments with 50mM and
100mM of H2O2 for 24 hours were not cytotoxic (viability at
50mM: 90.95+/28.16%; at 100mM: 86.36+/28.25%; p= 0.191
and p= 0.121, respectively). In cells treated with either dose, we
found a significant increase of Hsp60 at both the protein and
mRNA levels (Figure 4, A and B). The discrepancy between the
Hsp60 mRNA results obtained in vivo (no detectable mRNA
increase) and in vitro (significant increase) may be explained by the
fact that for the former experiments we extracted mRNA from the
whole mucosa whereas for the in vitro experiments we extracted the
mRNA from epithelial cells only. ELISA tests showed that Hsp60
release by treated cells into the extracellular medium was
significantly increased as compared with untreated cells (NT:
4.19 ng/ml; 50mM: 10.49 ng/ml; p,0.005; 100mM: 19.90 ng/ml;
p,0.001) (Figure 4, C).
NFkB-65 participated in the induction of the hsp60 gene
To understand how treatment with H2O2 induces hsp60 gene
up-regulation in epithelial cells and whether HSF-1 and NFkB-
p65, both considered pertinent Hsp transcription factors [16], are
involved, we investigated the levels of mRNA for HSF-1 and
NFkB-p65. They were present in all experimental conditions and
no significant differences were found between the stressed and
non-stressed cells (Figure 5, A). We then focused on NFkB-p65
because it has been reported that it is implicated in hsp60 gene
induction in heart cells [16]. Firstly, we searched by in in silico
analysis putative binding sites for NFkB-p65 in the hsp60 gene, and
found three, one of which was on the promoter (Table 5).
Subsequently we investigated by chromatin immunoprecipitation
(ChIP) assay the binding of NFkB-p65 to the site on the promoter.
The highest levels of binding were found in the gene from both, 50
and 100 mM of H2O2-treated cells, compared to untreated
counterparts (Figure 5, B). Therefore, NFkB-p65 appears to be
implicated in the up-regulation of the hsp60 gene and, thus, lead to
increased levels of Hsp60 in epithelial cells, which is accompanied
by its release into the extracellular medium. Hence, the possibility
exists for Hsp60 from epithelial cells of an inflamed airway mucosa
to reach other cells, such as neutrophils.
Discussion
Our study shows for the first time that in bronchial epithelium
the levels of Hsp60 and its co-chaperonin Hsp10, and Hsp40 are
significantly increased in patients with severe/very severe stable
COPD compared to non-smokers with normal lung function. The
Figure 4. Impact of oxidative stress on the levels of Hsp60 in a human bronchial epithelial cell line. Panel A: Western blotting showing
significantly increased levels of Hsp60 in 16HBE after treatment with 50 or 100 mM of H2O2 compared to untreated (UT) cells. The difference between
100 and 50 mM was also significant. Histograms represent the mean (SD) of the Hsp60/actin ratio. Panel B: RT-PCR showing significantly increased
levels of Hsp60 only after treatment with 100 mM of H2O2 compared to UT treated cells. Panel C: Hsp60 increased levels in the extracellular medium
(measured by ELISA tests) after treatment with 50 or 100 mM of H2O2 compared to untreated (UT) cells. ^: p,0.005; *: p,0.001.
doi:10.1371/journal.pone.0028200.g004
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same pattern was observed in lamina propria. Previous studies had
indicated a crucial role of Hsp60 in modulating immunity and
inflammation, particularly via the activation of macrophages and
neutrophils. For example, Hsp60 activates human monocytes and
macrophages by binding to CD14 with activation of p38MAPK
[17], and stimulates monocytes to synthesize pro-inflammatory
cytokines (such as TNFa, IL-12 and IL-15) and nitric oxide [18],
synergizing with IFN-c in inducing cytokine synthesis [19].
Extracellular Hsp60 can bind to the neutrophil’s membrane,
enhancing production of oxidants and release of proteases by it
[19].
Hsp60 can induce regulatory T cells (Tregs) differentiation via
the expression of FoxP3, the main transcription factor for Tregs in
cord blood mononuclear cells [20]. Moreover, Hsp60 can also
stimulate Tregs by both cell-to-cell contact and TLR2-mediated
secretion of TGFb and IL-10 [21], thus having anti-inflammatory
function. Conflicting results have been reported on expression of
FoxP3 in the airways of COPD patients [22,23]. In our study, the
levels of FoxP3 did not change significantly among groups and did
not correlate with Hsp60. Thus, it is unlikely that Hsp60 has anti-
inflammatory effects, at least through FoxP3 up-regulation, in
stable COPD.
Neutrophil numbers can be elevated in the bronchial mucosa of
stable COPD patients due to a variety of causes, including
augmented chemotaxis, increased adhesion to collagens, and
prolonged neutrophil survival [24]. The significant correlation we
found between the number of Hsp60-positive cells and neutrophils
in the bronchial mucosa of patients with stable COPD, suggests
that this chaperonin plays a role in controlling neutrophil functions
and bronchial inflammation in these patients. The Hsp60
molecules can be within and on the neutrophils and may originate
in the neutrophils themselves and in other cells (e.g., epithelial)
from which they gain the extracellular space and reach the
neutrophils. Our experiments with a bronchial-epithelial cell line
exposed to a pro-inflammatory stressor showed that Hsp60
expression increases during stress and is accompanied by its
release into the extracellular medium (see later). Thus, the Hsp60,
which augments in neutrophils of COPD mucosa, can be
produced by the neutrophils themselves or captured by them
from the extracellular space. The two mechanisms are possible
and not mutually exclusive.
Oxidative stress, a hallmark of COPD mucosa [25], is a potent
Hsp inducer, and Hsps may protect cells from death caused by
oxidative stress [26,27]. It is likely that the Hsp60 increase we
found in neutrophils enhances their survival and activation, a
situation that is likely to occur during bacterial infections often
present in the bronchial mucosa of patients with stable COPD
[28]. The possibility of infection will have to be investigated by
examining sputum and bronchoalveolar-lavage samples taking
before biopsy, samples that were not available for this study.
Our in vivo results led us to perform a set of in vitro experiments
to determine whether an oxidant and pro-inflammatory stress
(e.g., that caused by cell exposure to H2O2) induced Hsp60 up-
regulation and release by bronchial epithelial cells (cell line16-
HBE). We found that: 1) Hsp60 levels in 16HBE increase after
exposure to doses of H2O2 that do not affect cell viability; 2) The
increase of Hsp60 levels is accompanied by release of the
chaperonin in the extracellular medium; 3) Hsp60 increase is
due at least in part to overexpression of the chaperonin gene, and
in this up-regulation NFkB-p65 most likely plays a determinant
role as indicated by its capacity to bind the chaperonin-gene
promoter region. Furthermore, we have previously reported that
NFkB-p65 is overexpressed in bronchial biopsies of COPD
patients [29].
The results described above open new avenues for investigation,
for example those aiming at clarifying which pathways (Golgi,
exosomal, other) are involved in Hsp60 export from epithelial cells
and whether Hsp60 secreted from bronchial epithelial cells may
effectively cause activation of neutrophils.
Figure 5. Quantification of mRNA in the bronchial biopsies and binding of NFkB-p65 to the human hsp60-gene promoter region.
Panel A: Levels of HSF-1 and NFKB-p65 mRNA did not change significantly after treatment (50 or 100 mM of H2O2). Panel B: the binding of NFkB-p65 to
the hsp60 promoter was lower in untreated (UT) cells (lane 2) compared to the binding in cells treated with 50 or 100 mM of H2O2 (lanes 3 and 4,
respectively). Lanes: 1, Marker; 5, DNA UT Positive control; 6, DNA UT Negative control; and 7, Input DNA.
doi:10.1371/journal.pone.0028200.g005
Table 5. NFkB-p65 binding sites in the human hsp60 gene.
Gene
Predicted NFkB-p65
binding site (nt) Location
Human hsp60
(Acc NC_000002)
1) 342–356
2) 3274–3286
3) 12144–12156
Promoter
Intron
Intron
Primer used for ChIP assay
Site 1 forward reverse
342-356 59-cgcagggtgtgcagattg-39 59-ggcgagtgagggacagagt-39
doi:10.1371/journal.pone.0028200.t005
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With regard to the other Hsps that we found increased in
bronchial biopsies, it is known that Hsp10 – the Hsp60
intramitochondrial co-chaperonin, also known as Early Pregnancy
Factor [30] – has a potent immunosuppressive activity both in vivo
and in vitro [31–33]. Bronchial inflammation in patients with stable
COPD is characterized by the presence of activated Th1-Tc1 cells
[2,34]. We speculate that the Hsp10 increase observed in the
bronchial mucosa could modulate and/or repress the Th1-Tc1
type of inflammatory response.
We reported previously that Hsp60 and Hsp10 levels decrease
during carcinogenic steps in airways, i.e., from normal through
dysplastic to neoplastic mucosa [12,13]. COPD patients have a
higher risk for developing bronchial cancer than other pneumop-
athies. Hence, our data suggest that monitoring Hsp60 and Hsp10
levels in patients with COPD could help in the identification of a
subclass of patients (i.e., those in which Hsp60 and Hsp10 levels
suddenly decrease) which would have a higher risk for cancer
development.
The role of Hsp40 in bronchial inflammation is unclear. This
molecule has traditionally been studied as an Hsp70 co-chaperone
for its intracellular protein folding activity. In addition, Hsp40 up-
regulation is considered a good marker for endoplasmic reticulum
stress, particularly oxidative stress [35]. This information and our
observations reported here suggest that elucidating the role of
Hsp40 in the bronchial mucosa of stable COPD is promising
research line.
Our results showed no significant differences for Hsp27, Hsp70,
Hsp90, and pHSF-1 between stable COPD patients and controls.
These data are at first glance in contrast with a previous study that
demonstrated increased levels of these Hsps in the serum of
patients with stable COPD as compared to controls [36]. In this
previous study, however, no determinations were made on Hsps in
bronchial mucosa specimens as reported here. Our data could,
therefore, indicate that circulating Hsp27, Hsp70, and Hsp90,
found by others in COPD patients [36], do not originate in the
bronchial mucosa of greater bronchi but in other cells, e.g.,
peripheral airways or lung interstitial cells, or in other organs.
In conclusion, our data support the notion that Hsp60 can be
involved in COPD pathogenesis. Hsp60 levels increase in the
bronchial mucosa of patients with stable COPD and oxidative
stress could be an inducer of this increment. Up-regulation of the
hsp60 gene by oxidative stress with participation of NFkB-p65 is
probably responsible, at least in part, of the observed increase in
Hsp60. Both, the release of Hsp60 from bronchial epithelial cells
after an oxidant pro-inflammatory stimulus in vitro and the
association we found in the bronchial mucosa between neutrophils
and Hsp60 in vivo, favour the view that Hsp60 can be a marker of
disease severity in COPD. However, only further studies with
neutralization and/or administration of Hsp60 (first in animal
models) will reveal the actual role of this molecule in the
pathogenesis of COPD.
Materials and Methods
Subjects
All subjects were Caucasians and were recruited from the
Respiratory Medicine Unit of the ‘‘Fondazione Salvatore
Maugeri’’ (Veruno, Italy). The severity of the airflow obstruction
was staged using current GOLD criteria [1]. All former smokers
had stopped smoking for at least one year. COPD and chronic
bronchitis were defined, according to international guidelines, as
follows: COPD, presence of a post-bronchodilator forced
expiratory volume in one second (FEV1)/forced vital capacity
(FVC) ratio ,70%; chronic bronchitis; presence of cough and
sputum production for at least 3 months in each of two consecutive
years [1]. All COPD patients were stable with no previous
exacerbation in the six months before bronchoscopy. None of the
subjects was treated with theophylline, antibiotics, antioxidants,
mucolytics, and/or glucocorticoids in the month prior the
bronchial biopsy. The study conformed to the Declaration of
Helsinki and was approved by the ethic committee of the
Fondazione Salvatore Maugeri [Veruno (Novara), Italy] (Approval
number, up-dated on May 20, 2009, assigned by the local
Technical and Scientific Committee: p81). Written informed
consent was obtained from each subject and bronchial biopsies
were performed according to the local ethic committee guidelines.
Lung function tests and volumes
Pulmonary function tests were performed as previously
described [14] according to published guidelines [37]. Pulmonary
function tests included measurements of FEV1 and FEV1/FVC
under baseline conditions in all the subjects examined (6200
Autobox Pulmonary Function Laboratory; Sensormedics Corp.,
Yorba Linda, CA). In order to assess the reversibility of airflow
obstruction and post bronchodilator functional values the FEV1
and FEV1/FVC% measurements in the groups of subjects with
FEV1/FVC%#70% pre-bronchodilator was repeated 20 min
after the inhalation of 0.4 mg of salbutamol.
Fiberoptic bronchoscopy, collection and processing of
bronchial biopsies
Subjects were at the bronchoscopy suite at 8.30 AM after
having fasted from midnight and were pre-treated with atropine
(0.6 mg IV) and midazolam (5–10 mg IV). Oxygen (3 l/min) was
administered via nasal prongs throughout the procedure and
oxygen saturation was monitored with a digital oximeter. Using
local anaesthesia with lidocaine (4%) to the upper airways and
larynx, a fiberoptic bronchoscope (Olympus BF10 Key-Med,
Southend, UK) was passed through the nasal passages into the
trachea. Further lidocaine (2%) was sprayed into the lower
airways, and four bronchial biopsy specimens were taken from
segmental and subsegmental airways of the right lower and upper
lobes using size 19 cupped forceps. Bronchial biopsies for
immunohistochemistry and RT-PCR were gently extracted from
the forceps and processed for light microscopy as previously
described [14]. Two samples were embedded in Tissue Tek II
OCT (Miles Scientific, Naperville, IL), frozen within 15 min in
isopentane pre-cooled in liquid nitrogen, and stored at –80uC. The
best frozen sample was then oriented and 6mm thick cryostat
sections were cut for immunohistochemical light microscopy
analysis and 30mm thick cryostat sections were cut for RT-PCR
and processed as described below.
Immunohistochemistry
Two sections from each sample were stained applying
immunohistochemical methods with a panel of antibodies specific
for inflammatory markers or Hsps proteins (Table 6). Briefly, after
blocking non-specific binding sites with serum derived from the
same animal species as the secondary antibody, primary antibody
was applied at optimal dilutions in TRIS-buffered saline (0.15 M
saline containing 0.05 M TRIS-hydrochloric acid at pH 7.6) and
incubated 1hr at room temperature in a humid chamber.
Antibody binding was demonstrated with secondary antibodies
anti mouse (Vector, BA 2000), anti rabbit (Vector, BA 1000) or
anti goat (Vector, BA 5000) followed by ABC kit AP AK5000,
Vectastain and fast-red substrate (red color). Slides were included
in each staining run using human tonsil or nasal polyp as a positive
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control. For the negative control slides, normal goat, mouse or
rabbit non-specific immunoglobulins (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used at the same protein
concentration as the primary antibody.
Scoring system for immunohistochemistry
Morphometric measurements were performed with a light
microscope (Leitz Biomed, Leica Cambridge, UK) connected to a
video recorder linked to a computerized image system (Quantimet
500 Image Processing and Analysis System, Software Qwin
V0200B, Leica). Light-microscopic analysis was performed at a
magnification of 630x.
The immunostaining for all the antigens studied was scored
(range: 0 = absence of immunostaining to 3= extensive intense
immunostaining) in the intact (columnar and basal epithelial cells)
bronchial epithelium, as previously described [14]. The final result
was expressed as the average of all scored fields performed in each
biopsy. A mean6SD of 0.65060.240 millimeters of epithelium
was analyzed in COPD patients and control subjects.
Immunostained cells in lamina propria were quantified 100 mm
beneath the epithelial basement membrane in several non-
overlapping high-power fields until the whole specimen was
examined. The final result, expressed as the number of positive
cells per square millimeter, was calculated as the average of all the
cellular counts performed in each biopsy.
Double immunohistochemistry
Double immunostaining for identification of neutrophils
expressing Hsp60 was performed as described previously [29].
Briefly, primary antibodies, goat anti-Hsp60, and mouse anti-
neutrophil elastase (Table 6), were applied at the same dilutions as
for single staining in TRIS-buffered saline (0.15 M saline
containing 0.05 M TRIS-hydrochloric acid at pH 7.6) and
incubated 1hr at room temperature in a humid chamber.
Antibody binding was demonstrated with the use of secondary
antibodies anti mouse (Vector, BA 2000) and anti goat (Vector, BA
5000) followed by ABC kit AP AK5000, Vectastain and fast-red
substrate (red color) or ABC kit Elite PK6100, Vectastain,
followed by Diaminobenzidine substrate (brown color), respec-
tively. The immunostaining was scored as described above.
Quantification of Hsp mRNA levels in bronchial biopsies
Quantification of Hsps mRNA was performed in 9 patients with
severe/very severe COPD, 9 patients with mild/moderate COPD,
8 healthy smokers and 7 control non smokers randomly selected as
representative of the larger groups analysed for the immunohis-
tochemical study. Total RNA was extracted using the RNeasy
Lipid Tissue Mini Kit (Qiagen, 74804, Milan, Italy) from 30-mm
thick cryostat sections of bronchial biopsies following the
manufacturers’ instructions. Five nanograms of total RNA was
used for cDNA synthesis, using the Enhanced Avian HS RT-PCR
Kit (Sigma, HSRT100-1KT, Milan, Italy) and following the
manufacturer’s instructions. Primer pairs for Hsp10, Hsp40, and
Hsp60 (Invitrogen, Milan, Italy) were as follows: Hsp10 (NM_
002157) forward primer: cagtagtcgctgttggatcg; reverse primer:
gcctccatattctgggagaag; Hsp40 (NM_006145) DNAJB1 forward
primer: accagtggcccaggtaattt; reverse primer: ttgttccaactccccttcc;
and Hsp60 (NM_002156) forward primer: gaagaaaaaggctggctgaa;
reverse primer: tctccacagaaaggctgctt. Semiquantitative reverse
transcriptase-polymerase chain reaction (RT-PCR) was carried
out using the Enhanced Avian HS RT-PCR Kit (Sigma,
HSRT100-1KT, Milan, Italy) following the manufacturer’s pro-
tocol. The TotalLab TL120 program was used for quantification
of amplified bands density. Relative levels of mRNAs were
expressed as the ratio of optical density (OD) values of the gene of
interest/ OD values of the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
Cell cultures and treatments
We used the SV40 large T antigen–transformed 16HBE cell
line, a human bronchial epithelial cell line [38]. Cells were
cultured in Dulbecco-modified Eagle’s medium with 10% fetal calf
serum (FCS) and supplemented with 2 mM glutamine, 50 U/ml
penicillin, and 50 mg/streptomycin. Cells were grown as mono-
layers attached to the culture vessel and cultured at 37uC, 5%
CO2, in a humidified incubator. Passage number of cells used in
this study ranged from 12 to 35. Cell culture reagents were
purchased from GIBCO BRL LIFE Technologies (Invitrogen,
Italy). Prior to all the experiments, 70–80% cell monolayers were
incubated in serum–free medium for the 24 hours (hrs). The cells
were treated with different concentrations (0, 50 and 100mM) of
Table 6. Primary antibodies and conditions used for identification of inflammatory markers, Hsps, and pHSF-1 protein.
Primary antibodies
Target Supplier Catalog number Source Dilution Positive control
CD4 Dako M716 Mouse 1:100 Human tonsil
CD8 M7103 1:200
CD68 M814 1:200
Neutrophil elastase M752 1:100
Myeloperoxidase (MPO) M748 1:1000
FoxP3 R&D AF3240 Goat 1:60 Nasal polyp
Hsp10 Santa Cruz Biotechnology, Inc. Sc-20958 Rabbit 1:100 Nasal polyp
Hsp27 Sc-1048 Goat 1:200
Hsp40 Sc-1801 1:50
Hsp60 Sc-1052 1:100
Hsp70 Sc-1060 1:100
Hsp90 Sc-1055 1:150
pHSF1 Sc-30443R Rabbit 1:300
doi:10.1371/journal.pone.0028200.t006
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H2O2 for 24hrs. All experiments were performed at least in
triplicate.
MTT Assay for 16HBE viability
MTT [3-(4,5 dimethylthiazol-2yl)-2,5-diphenyltetrazolium bro-
mide] was obtained from Sigma (Italy). Briefly, 5x103 16HBE cells
were plated in 200ml of complete medium per well in 96-well
plates. Cells were treated as described in the previous paragraph
and after 24hrs the used medium was replaced with new one
containing MTT at a final concentration of 0.5mg/ml. After a 4-
hr incubation period, cells were solubilized in 200ml of DMSO/
well. Optical density (OD) was measured with a plate reader
(Titertel Multiskan MCC/340, Flow Laboratories, Switzerland) at
570nm (630nm as reference). Cell viability was expressed as the
percentage of OD value of treated cells compared with untreated
controls, according to the following equation: Viability = (OD
Samples/ OD Control) x100.
Cellular protein preparation and measurement from cell
cultures
Untreated and treated cells were lysed into ice-cold lysis solution
containing RIPA buffer, as previously described [38]. Lysates were
then spun at 16,0006g for 30 min at 4uC, the supernatant was
recovered, its protein concentration determined, and then stored
at 280uC until use. Intracellular proteins were quantified with the
Quant-iTTM protein assay kit (Invitrogen Molecular Probes, Italy),
using the Qubit fluorometer according to the manufacturer’s
instructions (the kit is accurate for protein concentrations ranging
from 12.5 mg/ml to 5 mg/ml).
Western Blotting
Briefly, 40 mg of proteins was added to 4x Laemmli buffer and
heated for 5 min at 95uC. Proteins were resolved by 12% SDS-
PAGE along with a molecular weight marker (Bio-RAD
Laboratories, Milan, Italy). Proteins were then transferred to
nitrocellulose membranes. After transfer, all membranes were
stained with Poinceau S to verify the quality of transfer and
loading similarity. Anti-Hsp60 (LK1) monoclonal antibody was
purchased from Sigma and used diluted 1:1000; anti-b actin (W27)
monoclonal antibody was purchased from Santa Cruz Biotech-
nologies (CA, USA) and used diluted 1:1,000. Horseradish
peroxidase-conjugated sheep anti-mouse antibody was purchased
from Amersham Biosciences (Ge Healthcare, Italy). Before
applying antibodies, the membranes were blocked with 5% not-
fat milk, and probed for 12 hrs with the specific antibody, followed
by incubation with horseradish peroxidase-conjugated second
antibody. Blots were detected using the ECL (Amersham
Bioscences) according to the manufacturer’s instructions. Densi-
tometric analysis of blots was performed using the NIH Image J
1.40 analysis program (National Institutes of Health, Bethesda,
MD, USA).
ELISA for Hsp60 level in cell culture supernatants of
16HBE cells
Quantitative comparison of Hsp60 levels in conditioned media
cell culture supernatants was performed by ELISA, using
commercial Hsp60 EIA kit from Stressgen Assay designs Inc
(Ann Arbor, MI USA) as described [38]. The results were
normalized for cell number and expressed as pg\ml\106 cells.
RNA extraction and quantification from 16HBE cells
The total RNA from untreated and treated cells was obtained
using Charge Switch Total RNA Cell Kits (Invitrogen) and the
quantity of RNA extracted was measured by Quant-IT RNA
Assay kit using the Qubit fluorometer according to the
manufacturer’s instructions.
RT-PCR with mRNA from 16HBE cells
RT-PCR was conducted with ImProm-II Reverse Transcriptase
kit (Promega) and GoTaq Green Master Mix kit (Promega)
according to the manufacturer’s instructions. We detected the
expression of Hsp60, HSF-1, and NFkB-p65 mRNAs using the
following primers: Hsp60 forward primer gttccgagagctgaatgagg,
reverse primer ctgagtcaggcccttctgtc; HSF1 forward primer
tgctgtttgagctgggaga, reverse primer cgtttgtcctactggggcta; and
NFkB-p65 forward primer gaccttttcaacttggcttcc, reverse primer
tgatgctgtggtcagaagga. mRNA was normalized using a housekeep-
ing gene (beta-actin) for each experimental condition. RT-PCR
products were separated on 1% agarose gel.
Chromatin immunoprecipitation (ChIP) assay
We first identified three NFkB-p65 binding sites in the human
hsp60 gene by sequence analysis with MatlNspector (version 7.7.3,
Genomatix, http://www.genomatix.de/) (Table 5). Chromatin
immunoprecipitation experiments were then performed to deter-
mine if NFkB-p65 would bind to the site identified in the promoter
(Table 5). We used the ChIP IT kit (Active Motif) according to the
manufacturer’s instructions, as described by Wang et al. [16].
Approximately 1.56107 cells (either untreated or after treatment
with H2O2) were fixed with formaldehyde (1% final concentration)
for 10min. Cross-linking was terminated by the addition of glycine
(1X final concentration). The chromatin was then cut into 150-
300-450 bp fragments using digestion enzymes for 15 min. The
chromatin was pre-cleared by adding Protein G beads to reduce
non-specific background. Then 10ml of the pre-cleared chromatin
was aliquoted as input. The rest of the pre-cleared chromatin of
each sample was separated into three groups by adding specific
antibody (NFkB-p65, C-20, Santa Cruz), positive control (RNApol
II), or negative control (IgG). The immunoprecipitated DNA was
eluted with ChIP elution buffer. The cross-linking was reversed
with 5M NaCl and RNA was removed with RNase A, followed by
digestion with proteinase K. The DNA was purified and PCR
analysis was performed using the primers described in Table 5 and
the products separated on a 3% agarose gel. PCR using the
GAPDH primers on DNA isolated with the RNA pol II antibody
(positive control) generated more product than similar reactions
performed on DNA isolated using IgG (negative control), as
described by manufacturer’s instructions. The results were
evaluated semi-quantitatively measuring the band intensity.
Statistical analysis
Group data were expressed as mean (standard deviation) for
functional data or median (range) or interquartile range (IQR) for
morphologic data. Differences between groups were analyzed
using analysis of variance (ANOVA) for functional and in vitro
data. The ANOVA test was followed by the unpaired t-test for
comparison between groups. The Kruskal Wallis test applied for
morphologic data was followed by the Mann-Whitney U test for
comparison between groups. Correlation coefficients were calcu-
lated using the Spearman rank method. Probability values of
p,0.05 were considered significant. Data analysis was performed
using the Stat View SE Graphics program (Abacus Concepts Inc.,
Berkeley, CA-USA).
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